Lilly ' s Tirzepatide Achieves All Primary and Key Secondary Study Outcomes Against Insulin Glargine in Adults with Type 2 Diabetes and Increased Cardiovascular Risk in SURPASS-4 Trial
INDIANAPOLIS, May 20, 2021 /PRNewswire/ -- Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses in adults with type 2 diabetes who have increased cardiovascular (CV) risk compared to titrated...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Cardiology | Cardiovascular | Clinical Trials | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Insulin | Lantus | Pharmaceuticals | Study